-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ChromaDex (NASDAQ:CDXC) PT Lowered to $5.50
ChromaDex (NASDAQ:CDXC) PT Lowered to $5.50
ChromaDex (NASDAQ:CDXC – Get Rating) had its price target reduced by HC Wainwright from $7.00 to $5.50 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other equities research analysts have also issued reports on CDXC. B. Riley lowered shares of ChromaDex from a buy rating to a neutral rating and decreased their target price for the company from $6.00 to $2.40 in a research note on Thursday, August 11th. Oppenheimer lowered shares of ChromaDex from an outperform rating to a market perform rating in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $5.48.
Get ChromaDex alerts:ChromaDex Stock Down 2.0 %
Shares of NASDAQ:CDXC opened at $1.45 on Monday. The firm has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.04. The firm has a market capitalization of $99.10 million, a P/E ratio of -3.54 and a beta of 1.71. ChromaDex has a 12-month low of $1.44 and a 12-month high of $8.75.
ChromaDex (NASDAQ:CDXC – Get Rating) last issued its earnings results on Wednesday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) EPS. Equities research analysts expect that ChromaDex will post -0.31 earnings per share for the current fiscal year.Insider Activity at ChromaDex
In other ChromaDex news, major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of ChromaDex stock in a transaction that occurred on Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, with a total value of $99,661.42. Following the purchase, the insider now owns 6,925,641 shares in the company, valued at $11,496,564.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. ProShare Advisors LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. Merriman Wealth Management LLC bought a new position in ChromaDex in the 1st quarter worth $29,000. Keebeck Alpha LP bought a new position in ChromaDex in the 4th quarter worth $56,000. Finally, XTX Topco Ltd bought a new position in ChromaDex in the 1st quarter worth $76,000. Institutional investors own 29.64% of the company's stock.
About ChromaDex
(Get Rating)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Macy's Value Lies Beneath its Stores
- The Mattel Train is Ready to Leave the Station
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
ChromaDex (NASDAQ:CDXC – Get Rating) had its price target reduced by HC Wainwright from $7.00 to $5.50 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
据The Fly报道,周一上午发给投资者的一份研究报告中,HC Wainwright将ChromaDex(纳斯达克代码:CDXC-GET评级)的目标价从7.00美元下调至5.50美元。HC Wainwright目前对该股的评级为买入。
A number of other equities research analysts have also issued reports on CDXC. B. Riley lowered shares of ChromaDex from a buy rating to a neutral rating and decreased their target price for the company from $6.00 to $2.40 in a research note on Thursday, August 11th. Oppenheimer lowered shares of ChromaDex from an outperform rating to a market perform rating in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $5.48.
其他一些股票研究分析师也发布了关于CDXC的报告。B.莱利在8月11日星期四的一份研究报告中将ChromaDex的股票评级从买入下调至中性,并将该公司的目标价从6.00美元下调至2.40美元。8月16日,周二,奥本海默在一份研究报告中将ChromaDex的股票评级从表现优于大盘下调至市场表现。三名股票研究分析师对该股的评级为持有,两名分析师对该公司股票的评级为买入。根据MarketBeat的数据,该公司的平均评级为持有,平均目标价为5.48美元。
ChromaDex Stock Down 2.0 %
ChromaDex股价下跌2.0%
Shares of NASDAQ:CDXC opened at $1.45 on Monday. The firm has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.04. The firm has a market capitalization of $99.10 million, a P/E ratio of -3.54 and a beta of 1.71. ChromaDex has a 12-month low of $1.44 and a 12-month high of $8.75.
纳斯达克:CDXC周一开盘报1.45美元。该公司的50日移动均线切入位在1.76美元,200日移动均线切入位在2.04美元。该公司的市值为9910万美元,市盈率为-3.54,贝塔系数为1.71。ChromaDex的12个月低点为1.44美元,12个月高位为8.75美元。
Insider Activity at ChromaDex
ChromaDex的内幕活动
In other ChromaDex news, major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of ChromaDex stock in a transaction that occurred on Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, with a total value of $99,661.42. Following the purchase, the insider now owns 6,925,641 shares in the company, valued at $11,496,564.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.80% of the stock is owned by company insiders.
在ChromaDex的其他消息中,大股东Hoi Shuen Solina Holly Chau在6月16日星期四的一笔交易中收购了600,037股ChromaDex股票。该股是以每股1.66美元的平均价格收购的,总价值为99,661.42美元。收购完成后,这位内部人士现在拥有该公司6925,641股,价值11,496,564.06美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个超级链接获得。11.80%的股份由公司内部人士持有。
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. ProShare Advisors LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. Merriman Wealth Management LLC bought a new position in ChromaDex in the 1st quarter worth $29,000. Keebeck Alpha LP bought a new position in ChromaDex in the 4th quarter worth $56,000. Finally, XTX Topco Ltd bought a new position in ChromaDex in the 1st quarter worth $76,000. Institutional investors own 29.64% of the company's stock.
机构投资者最近买卖了该公司的股票。Campbell&CO Investment Adviser LLC在第四季度购买了ChromaDex的一个新头寸,价值3.8万美元。ProShare Advisors LLC在第四季度购买了ChromaDex的一个新头寸,价值3.8万美元。Merriman Wealth Management LLC在第一季度购买了ChromaDex的一个新头寸,价值2.9万美元。Keebeck Alpha LP在第四季度购买了ChromaDex的一个新头寸,价值56,000美元。最后,XTX Topco Ltd在第一季度购买了ChromaDex的一个新头寸,价值7.6万美元。机构投资者持有该公司29.64%的股份。
About ChromaDex
关于ChromaDex
(Get Rating)
(获取评级)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex公司是一家专注于健康老龄化的生物科学公司。该公司通过三个部门运营:消费品;配料;以及分析参考标准和服务。它研究烟酰胺腺嘌呤二核苷酸(NAD+);直接向消费者和经销商提供含有其专利成分的成品膳食补充剂产品;开发基于专利的成分技术并将其商业化,并将这些成分作为原材料供应给消费品制造商。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Macy's Value Lies Beneath its Stores
- The Mattel Train is Ready to Leave the Station
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
- 免费获取StockNews.com在ChromaDex(CDXC)上的研究报告
- 梅西百货的价值隐藏在门店下面
- 美泰列车已准备好离开车站
- WallStreetBets股票华尔街(大多)看好
- 美光增加股息是否意味着是时候买入了?
- 什么是纳斯达克证券交易所?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChromaDex Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChromaDex和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧